comparemela.com

Latest Breaking News On - Aim immunotech chart - Page 1 : comparemela.com

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

14.02.2024 - Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus .

Jenene thomasExchange commissionImmunotech incPancreato biliary surgeonResponse evaluationPrivate securities litigation reform actInvestor contactAim immunotech chartIm immunotech kursIm immunotech aktie

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer

24.01.2024 - Subject enrollment is expected in Q1 2024OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center (“Erasmus .

United statesJenene thomasExchange commissionImmunotech incPrivate securities litigation reform actInvestor contactAim immunotech chartIm immunotech kursIm immunotech aktie

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

09.11.2023 - OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial .

United statesThomask equelsChristopher mcaleerImmunotech incTech incChief executive officerTech conferenceAim immunotech chartIm immunotech kursIm immunotech aktie

vimarsana © 2020. All Rights Reserved.